Recent advances in antiemetics: new formulations of 5HT₃-receptor antagonists

References

• Bloechl-DaumBDeusonRRMavrosPHansenMHerrstedtJDelayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatmentJ Clin Oncol200624274472447816983116
   PubMed Web of Science ®Google Scholar
• NavariRMManagement of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agentsDrugs201373324926223404093
   PubMed Web of Science ®Google Scholar
• CohenLde MoorCAEisenbergPMingEEHuHChemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settingsSupport Care Cancer200715549750317103197
   PubMed Web of Science ®Google Scholar
• HaideraliAMendittoLGoodMTeitelbaumAWegnerJImpact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. populationSupport Care Cancer201119684385120532923
   PubMed Web of Science ®Google Scholar
• van LaarESDesaiJMJatoiAProfessional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providersSupport Care Cancer201523115115725015057
   PubMed Web of Science ®Google Scholar
• CoatesAAbrahamSKayeSBOn the receiving end: patient perception of the side-effects of cancer chemotherapyEur J Cancer Clin Oncol19831922032086681766
   PubMedGoogle Scholar
• National Comprehensive Cancer NetworkNCCN clinical practice guidelines in oncology: antiemesis – v2.20182018 Available from: https://www.nccn.org/professionals/physician_gls/default.aspxAccessed May 25, 2018
   Google Scholar
• HeskethPJKrisMGGrunbergSMProposal for classifying the acute emetogenicity of cancer chemotherapyJ Clin Oncol19971511031098996130
   PubMed Web of Science ®Google Scholar
• GrunbergSMWarrDGrallaRJEvaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity: state of the artSupport Care Cancer201119Suppl 1S43S4720972805
   PubMedGoogle Scholar
• HilariusDLKloegPHvan der WallEvan den HeuvelJJGundyCMAaronsonNKChemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based studySupport Care Cancer201220110711721258948
   PubMed Web of Science ®Google Scholar
• NavariRM5-HT receptors as important mediators of nausea and vomiting due to chemotherapyBiochim Biophys Acta2015184810 Pt B2738274625838122
   PubMed Web of Science ®Google Scholar
• JanelsinsMCTejaniMAKamenCPeoplesARMustianKMMorrowGRCurrent pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patientsExpert Opin Pharmacother201314675776623496347
   PubMed Web of Science ®Google Scholar
• ShihTYXuYEltingLSCosts of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapyCancer2007110367868517567835
   PubMed Web of Science ®Google Scholar
• BurkeTAWisniewskiTErnstFRResource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital settingSupport Care Cancer201119113114020101417
   PubMed Web of Science ®Google Scholar
• NavariRMQinRRuddyKJOlanzapine for the prevention of chemotherapy-induced nausea and vomitingN Engl J Med2016375213414227410922
   PubMed Web of Science ®Google Scholar
• NavariRMManagement of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current AgentsBasel, HeidelbergSpringer2016
   Google Scholar
• HerrstedtJRoilaFWarrD2016 Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapySupport Care Cancer201725127728827443154
   PubMed Web of Science ®Google Scholar
• RoilaFWarrDHeskethPJ2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapySupport Care Cancer201725128929427510316
   PubMed Web of Science ®Google Scholar
• HeskethPJKrisMGBaschEAntiemetics: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201735283240326128759346
   PubMed Web of Science ®Google Scholar
• GilmoreJWPeacockNWGuAAntiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE studyJ Oncol Pract2014101687424065402
   PubMedGoogle Scholar
• AaproMMolassiotisADicatoMThe effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)Ann Oncol20122381986199222396444
   PubMed Web of Science ®Google Scholar
• SchwartzbergLHarrowBLalLSRadtchenkoJLymanGHResource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimensAm Health Drug Benefits20158527328226380034
   PubMed Web of Science ®Google Scholar
• KrautLFauserAAAnti-emetics for cancer chemotherapy-induced emesis: potential of alternative delivery systemsDrugs200161111553156211577793
   PubMed Web of Science ®Google Scholar
• HeskethPJGandaraDRSerotonin antagonists: a new class of anti-emetic agentsJ Natl Cancer Inst19918396136201850806
   PubMedGoogle Scholar
• Kytril (granisetron) injection, for intravenous use [prescribing information]San FranciscoGenentech2011
   Google Scholar
• van WijngaardenITulpMTSoudijnWThe concept of selectivity in 5-HT receptor researchEur J Pharmacol199018863013122164935
   PubMed Web of Science ®Google Scholar
• Anzemet tablets (dolasetron mesylate) [prescribing information]Bridgewater (NJ)Sanofi-Aventis2013
   Google Scholar
• Kytril (granisetron hydrochloride) tablets, oral solution [prescribing information]Nutley (NJ)Roche Laboratories2010
   Google Scholar
• Sustol (granisetron) extended-release injection, for subcutaneous use [prescribing information]Redwood (CA)Heron Therapeutics2016
   Google Scholar
• GabrailNYanagiharaRSpaczy skiMPharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two phase II trialsCancer Manag Res20157839225834466
   PubMed Web of Science ®Google Scholar
• Sancuso (granisetron transdermal system) [prescribing information]Bridgewater (NJ)ProStrakan2015
   Google Scholar
• Zofran (ondansetron hydrochloride) injection for intravenous use [prescribing information]Research Triangle Park (NC)GlaxoSmithKline2014
   Google Scholar
• Zofran (ondansetron hydrochloride) tablets [prescribing information]Research Triangle Park (NC)GlaxoSmithKline2016
   Google Scholar
• Aloxi (palonosetron HCl) injection for intravenous use [prescribing information]Woodcliff Lake (NJ)Eisai2015
   Google Scholar
• SmithHSCoxLRSmithEJ5-HT3 receptor antagonists for the treatment of nausea/vomitingAnn Palliat Med20121211512025841471
   PubMedGoogle Scholar
• Akynzeo (netupitant and palonosetron) capsules for oral use [prescribing information]Woodcliff Lake (NJ)Eisai2016
   Google Scholar
• GrallaRJBosnjakSMHontsaAA phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapyAnn Oncol20142571333133924631949
   PubMed Web of Science ®Google Scholar
• TsukaharaKNakamuraKMotohashiRAntiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomasActa Otolaryngol2014134111198120425315920
   PubMed Web of Science ®Google Scholar
• VidallCFernandez-OrtegaPCortinovisDJahnPAmlaniBScotteFImpact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational surveySupport Care Cancer201523113297330525953380
   PubMed Web of Science ®Google Scholar
• EglenRMLeeCHSmithWLPharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivoBr J Pharmacol199511448608667773547
   PubMed Web of Science ®Google Scholar
• RojasCThomasAGAltJPalonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor functionEur J Pharmacol20106262–319319919836386
   PubMed Web of Science ®Google Scholar
• WongEHClarkRLeungEThe interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitroBr J Pharmacol199511448518597773546
   PubMed Web of Science ®Google Scholar
• StoltzRParisiSShahAMacciocchiAPharmacokinetics, metabolism and excretion of intravenous [14C]-palonosetron in healthy human volunteersBiopharm Drug Dispos200425832933715378559
   PubMed Web of Science ®Google Scholar
• HeskethPJRossiGRizziGEfficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal studyAnn Oncol20142571340134624608196
   PubMed Web of Science ®Google Scholar
• AaproMRugoHRossiGA randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapyAnn Oncol20142571328133324603643
   PubMed Web of Science ®Google Scholar
• RapoportBLChasenMRGridelliCSafety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trialsLancet Oncol20151691079108926272769
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSModianoMRRapoportBLSafety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trialLancet Oncol20151691071107826272768
   PubMed Web of Science ®Google Scholar
• HeskethPJAaproMJordanKSchwartzbergLBosnjakSRugoHA review of NEPA, a novel fixed antiemetic combination with the potential for enhancing guideline adherence and improving control of chemotherapy-induced nausea and vomitingBiomed Res Int2015201565187926421300
   PubMed Web of Science ®Google Scholar
• AaproMSGrunbergSMManikhasGMA phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyAnn Oncol20061791441144916766588
   PubMed Web of Science ®Google Scholar
• SaitoMAogiKSekineIPalonosetron plus dexametha-sone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trialLancet Oncol200910211512419135415
   PubMed Web of Science ®Google Scholar
• NavariRMNagyCKGraySEThe use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapySupport Care Cancer20132161655166323314603
   PubMed Web of Science ®Google Scholar
• GrunbergSChuaDMaruASingle-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol – EASEJ Clin Oncol201129111495150121383291
   PubMed Web of Science ®Google Scholar
• NavariRMGraySEKerrACOlanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trialJ Support Oncol20119518819522024310
   PubMedGoogle Scholar
• SchnadigIDAgajanianRDakhilSRAPF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapyFuture Oncol201612121469148126997579
   PubMed Web of Science ®Google Scholar
• HeskethPJGrunbergSMGrallaRJThe oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 study groupJ Clin Oncol200321224112411914559886
   PubMed Web of Science ®Google Scholar
• Poli-BigelliSRodrigues-PereiraJCaridesADAddition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin AmericaCancer200397123090309812784346
   PubMed Web of Science ®Google Scholar
• SaitoHYoshizawaHYoshimoriKEfficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trialAnn Oncol20132441067107323117073
   PubMed Web of Science ®Google Scholar
• HuZChengYZhangHAprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trialSupport Care Cancer201422497998724276953
   PubMed Web of Science ®Google Scholar
• RaftopoulosHCooperWO’BoyleEGabrailNBocciaRGrallaRJComparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trialSupport Care Cancer201523372373225179689
   PubMed Web of Science ®Google Scholar
• GebbiaVCannataGTestaAOndansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting: results of a prospective randomized trialCancer1994747194519528082100
   PubMed Web of Science ®Google Scholar
• MatsumotoKTakahashiMSatoKPalonosetron or granisetron for prevention of CINV in patients with breast cancer receiving dexamethasone and fosaprepitant following anthracycline plus cyclophosphamide (AC) regimenJ Clin Oncol20153315 Suppl9598
   Web of Science ®Google Scholar
• SaitoMUomoriTMiuraKComparison between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy in breast cancer patients: according to recent multi-institutional double-blind randomized studySupport Care Cancer201725Suppl 2S054
   Google Scholar
• EisenbergPFigueroa-VadilloJZamoraRImproved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetronCancer200398112473248214635083
   PubMed Web of Science ®Google Scholar
• GrallaRLichinitserMvan der VegtSPalonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronAnn Oncol200314101570157714504060
   PubMed Web of Science ®Google Scholar
• WarrDGHeskethPJGrallaRJEfficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapyJ Clin Oncol200523122822283015837996
   PubMed Web of Science ®Google Scholar
• GrunbergSMDuganMMussHEffectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapySupport Care Cancer200917558959419037667
   PubMed Web of Science ®Google Scholar
• AaproMFabiANoleFDouble-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapyAnn Oncol20102151083108820080830
   PubMed Web of Science ®Google Scholar
• RapoportBLJordanKBoiceJAAprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a ran-domized, double-blind studySupport Care Cancer201018442343119568773
   PubMed Web of Science ®Google Scholar
• CelioLFrustaciSDenaroAPalonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trialSupport Care Cancer20111981217122520574663
   PubMed Web of Science ®Google Scholar
• BocciaRGrunbergSFranco-GonzalesERubensteinEVoisinDEfficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trialSupport Care Cancer20132151453146023354552
   PubMed Web of Science ®Google Scholar
• SchmittTGoldschmidtHNebenKAprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trialJ Clin Oncol201432303413342025225424
   PubMed Web of Science ®Google Scholar
• KomatsuYOkitaKYukiSOpen-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with palonosetronCancer Sci2015106789189525872578
   PubMed Web of Science ®Google Scholar
• NishimuraJSatohTFukunagaMCombination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trialEur J Cancer201551101274128225922233
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA drug safety communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate)2010 Available from: https://www.fda.gov/Drugs/Drug-Safety/ucm237081.htmAccessed October 10, 2017
   Google Scholar
• KolesarJMEickhoffJVermeulenLCSerotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different?Am J Health Syst Pharm201471650751024589542
   PubMed Web of Science ®Google Scholar
• YehYCBlouinGCReddyPEvidence to support use of palo-nosetron over generic serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomitingAm J Health Syst Pharm201471650050624589541
   PubMed Web of Science ®Google Scholar
• BotrelTEClarkOAClarkLPaladiniLFaleirosEPegorettiBEfficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysisSupport Care Cancer201119682383220495832
   PubMed Web of Science ®Google Scholar
• PopovicMWarrDGDeangelisCEfficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trialsSupport Care Cancer20142261685169724590374
   PubMed Web of Science ®Google Scholar
• HowellJSmeetsJDrenthHJGillDPharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomitingJ Oncol Pharm Pract200915422323119304880
   PubMedGoogle Scholar
• BocciaRVGordanLNClarkGHowellJDGrunbergSMEfficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III studySupport Care Cancer201119101609161720835873
   PubMed Web of Science ®Google Scholar
• SeolYMKimHJChoiYJTransdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV studySupport Care Cancer201624294595226265119
   PubMed Web of Science ®Google Scholar
• WokovichAMProdduturiSDoubWHHussainASBuhseLFTransdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attributeEur J Pharm Biopharm20066411816797171
   PubMed Web of Science ®Google Scholar
• MasonJWMoonTEUse and cardiovascular safety of transdermal and other granisetron preparations in cancer managementCancer Manag Res2013517918523930078
   PubMedGoogle Scholar
• OttoboniTGelderMSO’BoyleEBiochronomer technology and the development of APF530, a sustained release formulation of granisetronJ Exp Pharmacol20146152127186139
   PubMedGoogle Scholar
• HellerJBarrJBiochronomer technologyExpert Opin Drug Deliv20052116918316296743
   PubMedGoogle Scholar
• RaftopoulosHBocciaRCooperWO’BoyleEGrallaRJSlow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteriaFuture Oncol201511182541255126289588
   PubMed Web of Science ®Google Scholar
• CupissolDRSerrouBCaubelMThe efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesisEur J Cancer199026Suppl 1S23S272169782
   PubMed Web of Science ®Google Scholar
• de MulderPHSeynaeveCVermorkenJBOndansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, crossover studyAnn Intern Med1990113118348402146911
   PubMed Web of Science ®Google Scholar
• GrunbergSMStevensonLLRussellCAMcDermedJEDose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomitingJ Clin Oncol198978113711412526864
   PubMed Web of Science ®Google Scholar
• HeskethPNavariRGroteTDouble-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancerJ Clin Oncol1996148224222498708713
   PubMed Web of Science ®Google Scholar
• GelingOEichlerHGShould 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implicationsJ Clin Oncol20052361289129415718327
   PubMed Web of Science ®Google Scholar
• RoilaFWarrDClark-SnowRADelayed emesis: moderately emetogenic chemotherapySupport Care Cancer200513210410815549426
   PubMed Web of Science ®Google Scholar
• GrallaRJde WitRHerrstedtJAntiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trialsCancer2005104486486815973669
   PubMed Web of Science ®Google Scholar
• HeskethPJComparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomitingCancer Invest200018216317310705879
   PubMed Web of Science ®Google Scholar
• SchnadigIDAgajanianRDakhilSRPhase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trialCancer Manag Res2017917918728579832
   PubMed Web of Science ®Google Scholar
• SchwartzbergLMosierMGellerRBKlepperMJSchnadigIVogelzangNJAPF530 for nausea and vomiting prevention following cisplatin: phase 3 MAGIC trial analysisJ Community Support Oncol20171528288
   Google Scholar
• BaschEPrestrudAAHeskethPJAntiemetics: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201129314189419821947834
   PubMed Web of Science ®Google Scholar
• VardyJChiewKSGalicaJPondGRTannockIFSide effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapyBr J Cancer20069471011101516552437
   PubMed Web of Science ®Google Scholar
• RoscoeJAMorrowGRColagiuriBInsight in the prediction of chemotherapy-induced nauseaSupport Care Cancer201018786987619701781
   PubMed Web of Science ®Google Scholar
• AogiKSakaiHYoshizawaHA phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapySupport Care Cancer20122071507151421808994
   PubMed Web of Science ®Google Scholar
• BocciaRCooperWO’BoyleESustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapyJ Community Support Oncol2015132384625866983
   PubMedGoogle Scholar
• AlbanyCBramesMJFauselCJohnsonCSPicusJEinhornLHRandomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group studyJ Clin Oncol201230323998400322915652
   PubMed Web of Science ®Google Scholar
• LongoFMansuetoGLapadulaVCombination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapyInt J Clin Pract201266875375722805267
   PubMed Web of Science ®Google Scholar
• FeinbergBGilmoreJHaislipSImpact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapySupport Care Cancer201220361562321761096
   PubMed Web of Science ®Google Scholar
• GiraltSAManganKFMaziarzRTThree palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantationAnn Oncol201122493994620935058
   PubMed Web of Science ®Google Scholar
• du BoisAMeerpohlHGVachWKommossFGFenzlEPfleidererACourse, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetronEur J Cancer1992282–34504571534250
   PubMed Web of Science ®Google Scholar
• WarrDGStreetJCCaridesADEvaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapySupport Care Cancer201119680781320461438
   PubMed Web of Science ®Google Scholar
• TakeshimaNMatodaMAbeMEfficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trialSupport Care Cancer201422112891289824825735
   PubMed Web of Science ®Google Scholar
• DranitsarisGMolassiotisAClemonsMThe development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomitingAnn Oncol20172861260126728398530
   PubMed Web of Science ®Google Scholar
• TrammelMRoedererMPatelJMcLeodHDoes pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?Curr Oncol Rep201315327628523512709
   PubMed Web of Science ®Google Scholar
• de WitRAaproMBlowerPRIs there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?Cancer Chemother Pharmacol200556323123815838653
   PubMed Web of Science ®Google Scholar
• DixonCMColthupPVSerabjit-SinghCJMultiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humansDrug Metab Dispos19952311122512308591723
   PubMed Web of Science ®Google Scholar
• SanwaldPDavidMDowJCharacterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonistsDrug Metab Dispos19962456026098723743
   PubMed Web of Science ®Google Scholar
• HassanBAYusoffZBGenetic polymorphisms in the three Malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapyAsian Pac J Cancer Prev201112118519121517255
   PubMedGoogle Scholar
• AndersenRLJohnsonDJPatelJNPersonalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathwaysPharmacogenomics201617441743426871520
   PubMed Web of Science ®Google Scholar
• NakamuraHAriyoshiNOkadaKNakasaHNakazawaKKitadaMCYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomesCurr Drug Metab20056546948016248838
   PubMed Web of Science ®Google Scholar
• KaiserRSezerOPapiesAPatient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypesJ Clin Oncol200220122805281112065557
   PubMed Web of Science ®Google Scholar
• AaproMGranisetron: an update on its clinical use in the management of nausea and vomitingOncologist20049667368615561811
   PubMed Web of Science ®Google Scholar
• de LeonAPalonosetron (Aloxi): a second-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomitingProc (Bayl Univ Med Cent)200619441341617106506
   PubMedGoogle Scholar
• MorrisonDAndersonASlamaMPhase 1 bioavailability study comparing 2 different subcutaneous routes of administration for APF530Support Care Cancer201523Suppl111625315366
   PubMedGoogle Scholar
• BoyerEWShannonMThe serotonin syndromeN Engl J Med2005352111112112015784664
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA drug safety communication: new information regarding QT prolongation with ondansetron (Zofran)2012 Available from: http://www.fda.gov/Drugs/Drug-Safety/ucm310190.htmAccessed March 2, 2017
   Google Scholar
• MorganrothJFlahartyKKParisiSMoresinoCEffect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteersSupport Care Cancer201524262162726111957
   PubMed Web of Science ®Google Scholar
• SpinelliTMoresinoCBaumannSTimmerWSchultzAEffects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trialSpringerplus2014338925105088
   PubMed Web of Science ®Google Scholar
• MasonJWSelnessDSMoonTEO’MahonyBDonachiePHowellJPharmacokinetics and repolarization effects of intravenous and transdermal granisetronClin Cancer Res201218102913292122452942
   PubMed Web of Science ®Google Scholar
• MasonJWMoonTEO’BoyleEDietzAA randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongationCancer Manag Res2014618119024741326
   PubMed Web of Science ®Google Scholar
• BryggerLHerrstedtJ5-Hydroxytryptamine 3 receptor antagonists and cardiac side effectsExpert Opin Drug Saf201413101407142225196083
   PubMed Web of Science ®Google Scholar
• FeyerPJahnFJordanKProphylactic management of radiation-induced nausea and vomitingBiomed Res Int2015201589301326425557
   PubMed Web of Science ®Google Scholar
• SchwartzbergLProgress in chemoradiotherapy-induced nausea and vomitingLancet Oncol201617441241326952946
   PubMed Web of Science ®Google Scholar
• RuhlmannCHBelliCDahlTHerrstedtJPalonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin: a phase II studySupport Care Cancer201321123425343123949739
   PubMed Web of Science ®Google Scholar
• RuhlmannCHChristensenTBDohnLHEfficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trialLancet Oncol201617450951826952945
   PubMed Web of Science ®Google Scholar
• SuginoSJanickiPKPharmacogenetics of chemotherapy-induced nausea and vomitingPharmacogenomics201516214916025616101
   PubMed Web of Science ®Google Scholar
• TesaroTesaro announces fourth-quarter and full-year 2017 operating results2018 Available from: http://ir.tesarobio.com/news-releases/news-release-details/tesaro-announces-fourth-quarter-and-full-year-2017-operatingAccessed March 5, 2018
   Google Scholar